Clinical Trials
15 trialsNCT07137598 2026-05-04
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Hoffmann-La Roche
Phase 2 Recruiting
NCT01242488 2024-07-17
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT00048321 2022-12-05
ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis
Ionis Pharmaceuticals, Inc.
Phase 2 Completed
NCT02538341 2021-11-23
Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)
University of Alabama at Birmingham
Phase 2 Completed
NCT01960855 2021-08-24
A Study Investigating the Efficacy and Safety of ABT-494 Given With Methotrexate in Subjects With Rheumatoid Arthritis Who Failed Anti-Tumor Necrosis Factor (TNF) Biologic Therapy
AbbVie
Phase 2 Completed
NCT03001219 2020-01-29
A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy
Hoffmann-La Roche
Phase 2 Terminated
NCT02102594 2019-12-03
TAVAB
Charite University, Berlin, Germany
Phase 2 Terminated
NCT02882087 2019-04-03
A Study of the Efficacy and Safety of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Inadequate Response to TNF-α Antagonists Due to Treat Moderate and Severe Rheumatoid Arthritis
RemeGen Co., Ltd.
Phase 2 Terminated
NCT00094562 2019-01-18
A Fish Oil Supplement to Maintain Body Weight in Patients With Disease-Related Weight Loss
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT02862574 2018-06-27
Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis
Gilead Sciences
Phase 2 Terminated
NCT01715896 2016-10-31
A Study of Mavrilimumab Versus Anti Tumor Necrosis Factor in Subjects With Rheumatoid Arthritis
MedImmune LLC
Phase 2 Completed
NCT01390545 2016-04-13
VELVET
Takeda
Phase 2 Terminated
NCT00595413 2016-02-17
AUGUST II
EMD Serono
Phase 2 Completed
NCT01463059 2013-03-25
Efficacy and Safety of Olokizumab With Rheumatoid Arthritis With Previously Failed to Anti-tumor Necrosis Factor (Anti-TNF) Therapy
UCB Pharma
Phase 2 Completed
NCT00537667 2009-11-26
The SPECTRA Study
Swedish Orphan Biovitrum
Phase 2 Terminated